Original ArticlesUpregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Key Words
Cited by (0)
Nan Chen, Wenfeng Fang, and Jianhua Zhan contributed equally to this work.
This work was supported by grants from the Chinese National Natural Science Foundation project (Grant Nos. 81372502 and 81201917), the National High Technology Research and Development Program of China (863 Program Nos. 2012AA02A501 and 2012AA02A502), the Natural Science Foundation of Guangdong (Grant No. S2013010016564), the Major Project of Health Collaborative Innovation of Guangzhou City (201400000001-2), the Specialized Research Fund for the Doctoral Program of Higher Education (20120171120116), the Young Teacher Training Program of Sun Yat-Sen University (14ykpy38), the Physician-Scientist Cultivation Project of Sun Yat-Sen University Cancer Center (04140701), and Wu Jieping Medical Foundation Project (Grant No: 320.6750.131, 3206740.10012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Disclosures: The authors declare no conflicts of interest.